icon-folder.gif   Conference Reports for NATAP  
 
  HIV Glasgow 2026
8-11 November
Back grey_arrow_rt.gif
 
 
 
Patient-Reported Outcomes With Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV-1: Phase 3 Results Through Week 96
 
 
  Glasgow 2026 Nov 8-11
 

1109261copy

1109262copy

1109263copy

1109264copy

1109265copy

1109266copy

110926copy

1109268copy

1109269copy

11092610copy

11092611copy

11092612copy